Mivelsiran

DB19003InvestigationalGene Therapies

Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy).

Mechanism: Pharmacologically active on Amyloid-beta precursor protein
Curator reviewed
Code names: ALN-APP

Resolves to

Compound

Targets

What you can answer from here — as of October 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mivelsiran, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.